Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Tianyin Pharma Reports 70% Increase in First Half Revenues

publication date: Feb 15, 2008

Tianyin Pharma (OTCBB: VSCO) announced that it made a profit of $3.2 million on $14.9 million in revenue during the first six months of its fiscal 2008. Revenues were up 70% during the period, while net income increased 65%. The company said its growth was due to new distribution partners and a larger sales force. Although the numbers were up substantially year over year, 1st quarter and 2nd quarter figures were almost identical, making it seem as though the growth has stalled.  More details...

Stock Symbol: (OTCBB: VSCO)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital